MPLT
NASDAQMapLight Therapeutics Inc.
Price$36.55+1.86 (+5.36%)
01:30 PM07:45 PM
News · 26 weeks94-21%
2026-01-252026-07-19
Mix5290d
- Insider26(50%)
- SEC Filings16(31%)
- Analyst5(10%)
- Other4(8%)
- Leadership1(2%)
Latest news
25 items- ANALYSTBMO Capital Markets initiated coverage on MapLight Therapeutics with a new price targetBMO Capital Markets initiated coverage of MapLight Therapeutics with a rating of Outperform and set a new price target of $46.00
- INSIDERChief Discovery Officer Kreitzer Anatol sold $1,345,894 worth of Voting Common Stock (36,284 units at $37.09) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 174,906 units (SEC Form 4) to cover withholding tax4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERCAO and Interim CFO Gillis Jonathan sold $1,372,668 worth of Voting Common Stock (36,979 units at $37.12) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 144,240 units (SEC Form 4) to satisfy tax liability4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Executive Officer Kroeger Christopher A. sold $5,443,722 worth of Voting Common Stock (147,639 units at $36.87), decreasing direct ownership by 11% to 1,246,455 units (SEC Form 4) to satisfy withholding obligation4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Scientific Officer Lillie James Woodruff sold $673,636 worth of Voting Common Stock (18,267 units at $36.88), decreasing direct ownership by 8% to 224,462 units (SEC Form 4) to satisfy withholding obligation4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERGeneral Counsel Hanson Kristopher sold $607,870 worth of Voting Common Stock (16,508 units at $36.82), decreasing direct ownership by 10% to 145,823 units (SEC Form 4) to cover taxes4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Medical Officer Foff Erin Pennock sold $1,734,490 worth of Voting Common Stock (47,158 units at $36.78) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 298,901 units (SEC Form 4) (withholding obligation)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- INSIDERDirector Cox Troy was granted 7,864 units of Voting Common Stock (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Babler Martin was granted 7,864 units of Voting Common Stock (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Garnett Timothy John was granted 3,932 units of Voting Common Stock, increasing direct ownership by 8% to 53,457 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Luneborg Nanna Liebach was granted 3,932 units of Voting Common Stock (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Pavlov George was granted 3,932 units of Voting Common Stock, increasing direct ownership by 16% to 28,932 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Walker Maria C was granted 3,932 units of Voting Common Stock, increasing direct ownership by 7% to 62,703 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cox Troy3 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERSEC Form 3 filed by new insider Babler Martin3 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- ANALYSTRaymond James initiated coverage on MapLight Therapeutics with a new price targetRaymond James initiated coverage of MapLight Therapeutics with a rating of Strong Buy and set a new price target of $46.00
- SECSEC Form 8-K filed by MapLight Therapeutics Inc.8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Therapeutics Announces Changes to Board of DirectorsSAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Martin Babler and Troy Cox to its Board of Directors following their election at the Company’s Annual Meeting of Stockholders on June 23, 2026. Mr. Babler and Mr. Cox succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who did not stand for re-election and have concluded their service on the Board. Mr. Babler has been appointed as a member of the Audit Committee, and Mr. Cox has been appointed
- SECMapLight Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum DisorderThe IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD A prespecified analysis in adolescents with moderate to severe baseline irritability (ABC-I ≥ 16) demonstrated meaningful improvement on the care partner-reported ABC-I over placebo (effect size 1.33, nominal p=0.013). Consistent with this, analysis of the clinician-rated CGI-I in the irritability domain for the same subpopulation demonstrated clinically meaningful improvement over placebo (effect size 1.08, nominal p=0.036). Treatment effects were greater among adolescents with greater levels of baseline irritability ML-004 was generally well-tolerated, with no severe or serious a
- SECSEC Form 8-K filed by MapLight Therapeutics Inc.8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
MPLT FAQ
6 questionsWhere does MPLT stock trade?
MapLight Therapeutics Inc. (MPLT) is listed on NASDAQ.What sector and industry is MPLT in?
MapLight Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MapLight Therapeutics Inc. go public?
MapLight Therapeutics Inc. (MPLT) completed its IPO in 2025.What are analysts saying about MPLT?
MapLight Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Outperform with a $4600.00 price target on 2026-07-21. Recent price targets range from $3500.00 to $4800.00.What companies are similar to MPLT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MPLT side-by-side with any of them on Quantisnow.How can I track MPLT on Quantisnow?
Quantisnow aggregates MapLight Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MPLT to receive live email and push alerts on every new disclosure.